Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans

Vicagrel, a structural analog of clopidogrel, is now being developed as a thienopyridine antiplatelet agent in a phase II clinical trial in China. Some studies have shown that vicagrel undergoes complete first-pass metabolism in human intestine, generating the hydrolytic metabolite 2-oxo-clopidogrel...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jinfang, Chen, Xiaoyan, Zhong, Dafang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701912/
https://www.ncbi.nlm.nih.gov/pubmed/29209217
http://dx.doi.org/10.3389/fphar.2017.00846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701912/
https://www.ncbi.nlm.nih.gov/pubmed/29209217
http://dx.doi.org/10.3389/fphar.2017.00846

Ejemplares similares